Efficacy of Anlotinib combined with S-1 as the second-line treatment for advanced soft tissue sarcoma
Asian J Surg
.
2023 Feb;46(2):1050-1051.
doi: 10.1016/j.asjsur.2022.07.128.
Epub 2022 Aug 15.
Authors
Xiao-Jing Tie
1
,
Chen-Guang Yang
2
,
Yao-Hong Gao
3
,
Pei-Jie Liu
3
Affiliations
1
Department of Oncology, Kaifeng Central Hospital, Kaifeng, 475000, Henan, China. Electronic address: xiaojing_tie@163.com.
2
Department of Oncology, Luoyang Central Hospital, Luoyang, 471099, Henan, China.
3
Department of Oncology, Kaifeng Central Hospital, Kaifeng, 475000, Henan, China.
PMID:
35977858
DOI:
10.1016/j.asjsur.2022.07.128
No abstract available
Publication types
Letter
MeSH terms
Humans
Indoles / therapeutic use
Quinolines* / therapeutic use
Sarcoma* / drug therapy
Soft Tissue Neoplasms*
Substances
anlotinib
Indoles
Quinolines
S 1 (combination)